NVE Earnings Drop Despite 20 Years of Profitability

NVE (NVEC) reported its fiscal 2026 Q2 earnings on Jan 21, 2026, with revenue and net income below prior-year levels despite sustained profitability for over two decades. The company reiterated guidance for capacity expansion by March 2026 and highlighted growth in medical and industrial markets.

Revenue

Total revenue fell 6.1% to $6.35 million in 2026 Q2, driven by a 16% decline in contract R&D revenue and a 6% drop in product sales. Product sales, the largest revenue segment, accounted for $6.14 million, while contract R&D revenue totaled $208,220. The decline reflects a shift in product mix and lower distributor sales, though management emphasized long-term market opportunities in medical devices and automation.

Earnings/Net Income

Net income declined 17.8% to $3.31 million, with EPS falling 18.1% to $0.68. While the earnings contraction signals short-term challenges, the company’s ability to maintain profitability over 20+ years underscores operational resilience. The EPS decline, however, indicates margin pressure from lower-margin product sales and increased tax rates.

Post-Earnings Price Action Review

Shares of NVE edged down 0.80% on the latest trading day, offsetting a 7.44% weekly gain but reflecting a 3.50% month-to-date decline. The mixed performance highlights investor caution amid margin compression and sector-specific volatility. Analysts note that while Q3 results showed strong revenue growth, Q2’s weaker performance may temper near-term momentum.

CEO Commentary

CEO Dan Baker highlighted 23% revenue and 11% earnings growth in Q3 2026, driven by defense, non-defense, and distributor channels. Strategic priorities include leveraging wafer-level chip scale packaging for miniaturization, expanding medical device partnerships (e.g., Abbott’s extended agreement), and capitalizing on IoT/AIoT markets.

Guidance

NVE expects to deploy new production equipment by March 31, 2026, to boost capacity and in-house manufacturing. The company anticipates a 16%–17% effective tax rate for 2026, supported by $700,000–$1 million in manufacturing tax credits. Qualitative guidance emphasizes growth in distributor sales and R&D monetization, with quantitative expectations aligned to Q3 results: $6.35 million revenue, $0.68 EPS, and $3.31 million net income.

Additional News

Recent developments include a 23% year-over-year revenue surge in Q3 2026, driven by a 335% spike in contract R&D revenue and 16% growth in product sales. NVE also announced a new wafer-level chip scale sensor (0.65mm²) and extended its partnership with Abbott through 2027. Institutional investors, including Jane Street and the Tennessee Department of Treasury, increased stakes in Q1–Q2 2026.

Financial Health

NVE’s balance sheet remains robust, with a current ratio of 29.63 and a low debt-to-equity ratio of 0.02. Despite margin compression, the company’s net margin of 55.79% and operating margin of 59.11% reflect efficient cost management. Analysts at Weiss Ratings maintain a “Hold” rating, while institutional ownership stands at 65.95%.

Strategic Outlook

With new equipment operational by late Q1 2026, NVE aims to capitalize on high-sensitivity sensor demand in robotics, smart factories, and medical devices. CEO Baker emphasized recurring revenue potential through customer retention and product diversification, targeting growth rates exceeding customer demand. The company’s focus on miniaturization and MRAM IP licensing positions it to benefit from emerging markets.